# Lipoic Acid for Progressive Multiple Sclerosis (MS)

> **NCT03161028** · PHASE2 · COMPLETED · sponsor: **VA Office of Research and Development** · enrollment: 115 (actual)

## Conditions studied

- Multiple Sclerosis

## Interventions

- **DRUG:** Lipoic acid
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03161028
- **Lead sponsor:** VA Office of Research and Development
- **Sponsor class:** FED
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-08-17
- **Primary completion:** 2023-12-31
- **Final completion:** 2024-06-30
- **Target enrollment:** 115 (ACTUAL)
- **Last updated:** 2025-03-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03161028

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03161028, "Lipoic Acid for Progressive Multiple Sclerosis (MS)". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03161028. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*